NCBiotech News

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Durham-based BioCryst Pharmaceuticals’ berotralstat a positive scientific opinion through the Early Access to Medicines Scheme.

The FDA has approved a once-daily capsule developed by Durham's BioCryst Pharmaceuticals to prevent the life-threatening attacks of swelling in people with the rare disease called hereditary angioedema, or HAE.

An NCBiotech contract drug development and manufacturing portfolio company, KBI Biopharma, will establish a new $150M, 200-employee manufacturing facility near RTP.

North Carolina’s Small Business and Technology Development Center is hosting a two-day workshop for entrepreneurs starting Wednesday, Dec. 2

Former Duke University science educator and researcher and NCBiotech board member James (Jim) Siedow, Ph.D., has died. 

Academic scientists at NC universities receive the first seed grants from the Amnion Foundation for research projects that will study cells derived from birth tissue to better understand fetal health and cancer.

Verona Pharma has landed an additional $30 million in financing to support its “first-in-class” drug candidate, ensifentrine, targeting chronic obstructive pulmonary disease (COPD).

Eli Lilly and Durham gene editing innovator Precision Biosciences announced a research collaboration and exclusive license agreement that could potentially be worth over $2.7 billion.

Kimberly Smith, M.D., MPH, SVP and head of research and development of ViiV Healthcare in RTP, is hailed as one of the top 20 among 2020’s "Fiercest Women in Life Sciences."

IPM Chirana, a global company that makes ventilators to treat critical care patients, has selected Research Triangle Park as the site of its U.S. headquarters.

Morrisville-based Locus Biosciences has signed an agreement with a global non-profit to help fund a new CRISPR Cas3 antibacterial therapy to treat recurrent urinary tract infections.

Verona Pharma, a British clinical-stage biotech firm with U.S. headquarters in Raleigh, is exploring the option of repurposing its leading drug candidate to treat COVID-19 patients.

NCBiotech awarded 11 grants and loans totaling $623,136 to bioscience companies, universities and nonprofit organizations in the first quarter of its fiscal year.

Avient Biosciences' new hemp and research and extraction facility is prepared to produce pharmaceutical ingredients.

Merck enters an agreement to buy clinical-stage startup VelosBio for $2.75 billion.